Log in

Relevant bibliographies by topics / Cancer tumer / Journal articles

To see the other types of publications on this topic, follow the link: Cancer tumer.

Journal articles on the topic 'Cancer tumer'

Author: Grafiati

Published: 6 September 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer tumer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Battah, Arwa, Iyad Farouji, Theodore DaCosta, et al. "S2447 Tumer Lysis Syndrome - A Rare Complication of Gastric Cancer After Initiation of Keytruda." American Journal of Gastroenterology 118, no. 10S (2023): S1716. http://dx.doi.org/10.14309/01.ajg.0000959428.89405.12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Blaich, Günter, Hella Raade, and Manfred Metzler. "Modification of 7,8–benzoflavone metabolism in hamster liver and kidney microsomes by hepatic tumer inducing treatments." Carcinogenesis 11, no. 1 (1990): 95–101. http://dx.doi.org/10.1093/carcin/11.1.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Parsons, Heather A., Timothy Blewett, Xiangying Chu, et al. "Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030." Cancer Research 83, no. 5_Supplement (2023): PD11–06—PD11–06. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd11-06.

Full text

Abstract:

Abstract Background. Patients (pts) with early triple negative breast cancer (eTNBC) are at increased risk of breast cancer recurrence and death. Recent studies have focused on escalation of therapy, with current treatment standard of at least five drugs – and associated toxicities - for eTNBC. Though presence of residual disease after neoadjuvant therapy (NAT) as measured by residual cancer burden (RCB) helps guide addition of adjuvant treatment, more effective tools to tailor therapy are limited. Persistence of circulating tumor DNA (ctDNA) in the setting of residual disease is associated wi

APA, Harvard, Vancouver, ISO, and other styles

4

Curran, Paytin, DeLaney Anderson, Jeffrey Okojie, et al. "Abstract 5034: Comparative whole genome sequencing between matched cryopreserved and FFPE tumor samples." Cancer Research 85, no. 8_Supplement_1 (2025): 5034. https://doi.org/10.1158/1538-7445.am2025-5034.

Full text

Abstract:

Background & Aims: Next generation sequencing, specifically whole genome sequencing (WGS), plays a key role in precision medicine. Currently, the main source of cancer biospecimens for WGS is formalin-fixed, paraffin-embedded (FFPE) tissues. This is partly because cryopreserved (CP) tissues have not been routinely stored in real-world clinical settings. This study aimed to compare the outcomes of WGS by using matched CP and FFPE samples. We hypothesized that CP samples would demonstrate superior quality metrics before and after sequencing the DNA. Methods: A total of 50 matched pairs of CP

APA, Harvard, Vancouver, ISO, and other styles

5

Cho, Bong Jun, Hans H. Kim, David J. Lee, et al. "MicroRNA-21 inhibitor potentiates anti-tumor effect of radiation therapy in vitro and in vivo." Tumor Microenvironment and Therapy 2, no. 1 (2014): 1–13. http://dx.doi.org/10.2478/tumor-2014-0001.

Full text

Abstract:

AbstractMicroRNA-21 (miR-21) plays important roles in carcinogenesis and is highly expressed in diverse human cancers. We evaluated the potential of targeting miRNA-21 to overcome the radioresistance of human cancer cells having an activated EGFR2-associated signaling and also aimed to elucidate the mechanisms of radiosensitization, and the effect on epithelial- mesenchymal transition (EMT). Ectopic overexpression of miR-21 up-regulated EGFR/HER2-associated signaling and increased radioresistance of a panel of human cancer cells (U251, U87, and A549 cells). In contrast, a specific inhibitor of

APA, Harvard, Vancouver, ISO, and other styles

6

Lavekar, G. S. "Arbud-Tumor-Cancer- a concise integrative review." Journal of Clinical Oncology Reports 1, no. 1 (2023): 01–05. http://dx.doi.org/10.58489/2836-5062/001.

Full text

Abstract:

The Cancerous diseases will cause 10 million deaths in 2020 and may increase in coming years (1). Since ancient times Cancer-Arbud has been considered a mega disease and critical for treatment. A review is presenting the conception, description and treatment modalities as described in ayurveda, a short review is presented in this article.

APA, Harvard, Vancouver, ISO, and other styles

7

GARCÍA CEBRIÁN, MARÍA JOSÉ, MONIKA BAUDEN, ROLAND ANDERSSON, STEFAN HOLDENRIEDER, and DANIEL ANSARI. "Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?" Anticancer Research 36, no. 9 (2016): 4381–90. http://dx.doi.org/10.21873/anticanres.10981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Swathi, Madhavan* T. Keerthana A. Sowmiya D. Kilimozhi. "T Cell Line Treatment for Cancer Using Tumor-Infiltrating Lymphocytes." International Journal of Pharmaceutical Sciences 2, no. 11 (2024): 1653–68. https://doi.org/10.5281/zenodo.14245431.

Full text

Abstract:

The understanding about tumor-infiltrating lymphocytes (TIL) plays a monumental role in the treatment of cancer, creating a hitting spot in immuno-oncology. Apart from being used as a prognostic marker for other chemotherapy, TIL places its own importance in the treatment as well. TIL therapy uses autologous tumor-infiltrating lymphocytes extracted from the tumor following the expansion in an in vitro manner. After completing lymphodepletion, the patient was ready to receive the TIL therapy. Herein, we concisely describe the process of preparing TIL for therapy. Later, we emphasize the role of

APA, Harvard, Vancouver, ISO, and other styles

9

Masood, Behzad, Afzaal Aleem Khan, Muhammad Usman, et al. "Institution Based Tumor Registry, Benazir Bhutto Hospital: A Four Year Data Based Analysis." Journal of Rawalpindi Medical College VOL 23 NO S-1 (2019): STUDENTS SUPPLEMENT, no. 23(S-1) (2019): 37–41. https://doi.org/10.5281/zenodo.5684784.

Full text

Abstract:

Background: To retrieve all diagnosed cancer cases during the past four years (2014-2017) in Benazir Bhutto Hospital, Rawalpindi, and categorize them by organ sites affected/ topographically, to determine cancers with the highest prevalence in our part of the world. Materials & Methods: A hospital registry-based retrospective study was undertaken in the Department of Pathology of Benazir Bhutto Hospital, Rawalpindi. All diagnosed cases of cancer for the past four years that had been histologically confirmed, were retrieved. The cancer cases thus obtained were then classified topographicall

APA, Harvard, Vancouver, ISO, and other styles

10

Shalini, Das, Jahan Nushrat, and Mal Chittabrata. "In-silico Identification of lncRNA Functionality in Cancers Related to Obesity." International Journal of BioSciences and Technology (IJBST) ISSN: 0974-3987 13, no. 3 (2020): 34–41. https://doi.org/10.5281/zenodo.4275605.

Full text

Abstract:

<strong><em>In-silico</em> Identification of lncRNA Functionality in Cancers Related to Obesity</strong> Shalini Das, Nushrat Jahan and Chittabrata Mal Amity Institute of Biotechnology, Amity University Kolkata, Rajarhat, Newtown, Action Area III, North 24 PGS, 700135, INDIA shweata7@gmail.com, nushratjahan8456@gmail.com, cmal@kol.amity.edu   <strong>ABSTRACT:</strong> Investigating the gene expression networks that regulate cancer initiation and development is crucial but remains mostly incomplete. With the innovations in RNA-sequencing technologies and computational biology, long noncod

APA, Harvard, Vancouver, ISO, and other styles

11

SK, Deshmukh. "Immune Cells in the Tumor Microenvironment and Cancer Stem Cells: Interplay for Tumor Progression." Journal of Embryology & Stem Cell Research 2, no. 2 (2018): 1–2. http://dx.doi.org/10.23880/jes-16000109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Fejzić, Hanifa. "Tumor marker CA 15-3 in breast cancer patients." Acta Medica Academica 44, no. 1 (2015): 39–46. http://dx.doi.org/10.5644/ama2006-124.125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ostojić, Marija, Ana Djurić, Kristina Živić, and Jelena Grahovac. "Analysis of the nischarin expression across human tumor types reveals its context-dependent role and a potential as a target for drug repurposing in oncology." Plos One 19, no. 5 (2023): 0299685. https://doi.org/10.1371/journal.pone.0299685.

Full text

Abstract:

Abstract Nischarin was reported to be a tumor suppressor that plays a critical role in breast cancer initiation and progression, and a positive prognostic marker in breast, ovarian and lung cancers. Our group has found that nischarin had positive prognostic value in female melanoma patients, but negative in males. This opened up a question whether nischarin has tumor type-specific and sex-dependent roles in cancer progression. In this study, we systematically examined in the public databases the prognostic value of nischarin in solid tumors, regulation of its expression and associated signalin

APA, Harvard, Vancouver, ISO, and other styles

14

Chandana, Kamili a. *. Shafeen Begum a. Abbulu Konda a. Ravi Shankar Kakaraparthi b. Uma Maheshwararao Vattikutti c. "NANO-ANTIANGIOGENESIS IN CANCER THERAPY." Journal of Pharma Research 8, no. 5 (2019): 244–49. https://doi.org/10.5281/zenodo.2678000.

Full text

Abstract:

<strong><em>ABSTRACT</em></strong> <strong><em>C</em></strong><em>ancer angiogenesis is the growth of new blood vessels that tumors need to grow. This process is caused by the release of chemicals by the tumor and by host cells near the tumor. Antiangiogenesis can treat the cancer from the root cause and design of the potent anti angiogenic agents in the nano-form will give a target specific action, decreasing the side effects. In this review, an overview of mechanism of antiangiogenic treatment and role of nanoformulations is being presented. Studies on nano-antiangiogenesis will advance our

APA, Harvard, Vancouver, ISO, and other styles

15

Tavartkiladze, Alexandre, Gaiane Simonia, Ruite Lou, et al. "Exploring AminoSineTriComplex (AminoTriComplex) for Multimodal Tumor Management in Carcinogen-Induced Rat Models: Insights from Blood Biomarker Analysis." Journal of Cancer Research 2, no. 1 (2024): 1–18. https://doi.org/10.64030/2578-3726.02.01.13.

Full text

Abstract:

Cancer remains one of the leading causes of mortality worldwide, with traditional treatments often facing significant challenges in terms of efficacy, resistance, and toxicity. As cancers progress to advanced stages, they frequently develop resistance to monotherapies, underscoring the need for multi-targeted treatments that can address the complexity of tumor biology. AminoSineTriComplex, a formulation of bioactive compounds derived from various medicinal plants, represents a promising multi-targeted approach to oncological therapy. This study explores the effects of AminoSineTriComplex acros

APA, Harvard, Vancouver, ISO, and other styles

16

Arbia, Abbes, Boudemia Rihab, and Rechreche Hocine. "BENEFITS OF METFORMIN USE BY BREAST AND COLORECTAL CANCER PATIENTS WITH TYPE 2 DIABBETES MILLITUS: A CASE-CONTROL STUDY IN JIJEL PROVINCE (ALGERIA)." Journal of Applied Biological Sciences 17, no. 2 (2023): 375–90. https://doi.org/10.5281/zenodo.8018993.

Full text

Abstract:

Colorectal cancer and breast cancer are the most diagnosed cancers in Algeria. Recent studies have indicated that metformin is the first-line therapy treatment for type 2 diabetes mellitus; it may be a potential chemoprevention agent. In order to better understand the effect of metformin use on the prognosis of colorectal cancer and breast cancer in patients with type 2 diabetes mellitus, we focused mainly on the study of the tumor markers carcinoembryonic antigen and carbohydrate antigen 19-3/15-3. In this study, patients diagnosed with both colorectal cancer, breast cancer and diabetes melli

APA, Harvard, Vancouver, ISO, and other styles

17

Detrés Román, Carlos R., Megan M. Erwin, Michael W. Rudloff, et al. "Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control." Journal for ImmunoTherapy of Cancer 12, no. 10 (2024): e009129. http://dx.doi.org/10.1136/jitc-2024-009129.

Full text

Abstract:

BackgroundImmune checkpoint blockade (ICB) therapies are an important treatment for patients with advanced cancers; however, only a subset of patients with certain types of cancer achieve durable remission. Cancer vaccines are an attractive strategy to boost patient immune responses, but less is known about whether and how immunization can induce long-term tumor immune reprogramming and arrest cancer progression. We developed a clinically relevant genetic cancer mouse model in which hepatocytes sporadically undergo oncogenic transformation. We compared how tumor-specific CD8 T cells (TST) diff

APA, Harvard, Vancouver, ISO, and other styles

18

Shashi, Ranjan, and Bharti Ramendra. "Correlation between Breast Cancer Grading, Staging, and Hormone Receptor Status in Rural India: A Comprehensive Study." International Journal of Pharmaceutical and Clinical Research 16, no. 5 (2024): 2907–11. https://doi.org/10.5281/zenodo.13823771.

Full text

Abstract:

<strong>Background:</strong> Breast cancer is the most common cancer among women worldwide and a leading cause of cancer-related mortality in India. Significant disparities exist in the diagnosis and treatment of breast cancer between urban and rural populations, with rural women often presenting with more advanced stages of the disease. Understanding the correlation between tumor characteristics and hormone receptor status in rural settings is crucial for improving patient outcomes. <strong>Aim:</strong> This study aims to analyze the correlation between breast cancer grading,

APA, Harvard, Vancouver, ISO, and other styles

19

Li, Lin, Mengyuan Li, Zehang Jiang, and Xiaosheng Wang. "ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer." Cells 8, no. 7 (2019): 678. http://dx.doi.org/10.3390/cells8070678.

Full text

Abstract:

Because traditional treatment strategies for advanced gastrointestinal (GI) cancers often have a limited therapeutic effect, immunotherapy could be a viable approach for the therapy of advanced GI cancers, considering the recent success of immunotherapy in treating various refractory malignancies, including the DNA mismatch repair-deficient GI cancers. However, only a subset of cancer patients currently respond to immunotherapy. Thus, it is important to identify useful biomarkers for predicting cancer immunotherapy response. The tumor suppressor gene ARID1A has a high mutation rate in GI cance

APA, Harvard, Vancouver, ISO, and other styles

20

Zhang, Chunfeng, Chenyu Hu, Kunqi Su, et al. "The Integrative Analysis of Thrombospondin Family Genes in Pan-Cancer Reveals that THBS2 Facilitates Gastrointestinal Cancer Metastasis." Journal of Oncology 2021 (November 10, 2021): 1–19. http://dx.doi.org/10.1155/2021/4405491.

Full text

Abstract:

Recent cancer studies have found that the thrombospondin (THBS) family, including THBS1, THBS2, THBS3, THBS4, and THBS5, play vital roles in the development and progression of human cancers. However, their relationships with tumor stage, prognosis, and tumor immunity in pan-cancer have not been systematically reported. In the present study, we employed versatile public databases to assess the expression and mutations of different THBSs in pan-cancer and performed functional experiments to analyze the roles of THBS2 in gastrointestinal cancer metastasis. Our findings indicate that THBS genes ar

APA, Harvard, Vancouver, ISO, and other styles

21

Nenciu, Adina-Elena, C. G. Nenciu, R. Fodoroiu, Florica Șandru, and M. C. Dumitrașcu. "TUMOR MARKERS IN OVARIAN CANCER." Journal of Surgical Sciences 7, no. 2 (2020): 79–84. http://dx.doi.org/10.33695/jss.v7i2.356.

Full text

Abstract:

Even if today’s society is rapidly evolving there is still much that can be done. This applies in theoncological field. One of the main female health problems worldwide is represented by thegynecological cancers. Ovarian cancer is the main cause of mortality among women withgynecological cancers. Although its prevalence is lover compared to breast, uterine or cervicalcancer, the mortality and morbidity rates are significantly higher. The first step in the managementof ovarian cancer is represented by regular screening and rapid diagnosis. One of the most importanttolls is represented by serolo

APA, Harvard, Vancouver, ISO, and other styles

22

Da Gama Duarte, Jessica, Luke T. Quigley, Anna Rachel Young, et al. "Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies." International Journal of Molecular Sciences 22, no. 20 (2021): 11220. http://dx.doi.org/10.3390/ijms222011220.

Full text

Abstract:

Ovarian cancers include several disease subtypes and patients often present with advanced metastatic disease and a poor prognosis. New biomarkers for early diagnosis and targeted therapy are, therefore, urgently required. This study uses antibodies produced locally in tumor-draining lymph nodes (ASC probes) of individual ovarian cancer patients to screen two separate protein microarray platforms and identify cognate tumor antigens. The resulting antigen profiles were unique for each individual cancer patient and were used to generate a 50-antigen custom microarray. Serum from a separate cohort

APA, Harvard, Vancouver, ISO, and other styles

23

Kashyap, Poonam. "Ovarian tumor: a review." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 9 (2021): 3657. http://dx.doi.org/10.18203/2320-1770.ijrcog20213510.

Full text

Abstract:

Ovarian cancers are the 7th most common cancers in women. It is found more commonly in elderly age group. The survival depends on the stage of diagnosis and many of the patients present in advanced disease when the prognosis becomes dismal. The dilemma is to differentiate them from benign disease so that the unwanted laparotomies could be saved. Biomarkers and radiological classification may play a role in differentiating benign from malignant and deciding on the management. There is no screening method to diagnose ovarian cancers and the patient presents with nonspecific complaints missing th

APA, Harvard, Vancouver, ISO, and other styles

24

Margul, Daniel, Camilla Yu, and Mariam M. AlHilli. "Tumor Immune Microenvironment in Gynecologic Cancers." Cancers 15, no. 15 (2023): 3849. http://dx.doi.org/10.3390/cancers15153849.

Full text

Abstract:

Gynecologic cancers have varying response rates to immunotherapy due to the heterogeneity of each cancer’s molecular biology and features of the tumor immune microenvironment (TIME). This article reviews key features of the TIME and its role in the pathophysiology and treatment of ovarian, endometrial, cervical, vulvar, and vaginal cancer. Knowledge of the role of the TIME in gynecologic cancers has been rapidly developing with a large body of preclinical studies demonstrating an intricate yet dichotomous role that the immune system plays in either supporting the growth of cancer or opposing i

APA, Harvard, Vancouver, ISO, and other styles

25

Duval, Adrian, Cheryl Jeanneret, Tania Santoro, and Olivier Dormond. "mTOR and Tumor Cachexia." International Journal of Molecular Sciences 19, no. 8 (2018): 2225. http://dx.doi.org/10.3390/ijms19082225.

Full text

Abstract:

Cancer cachexia affects most patients with advanced forms of cancers. It is mainly characterized by weight loss, due to muscle and adipose mass depletion. As cachexia is associated with increased morbidity and mortality in cancer patients, identifying the underlying mechanisms leading to cachexia is essential in order to design novel therapeutic strategies. The mechanistic target of rapamycin (mTOR) is a major intracellular signalling intermediary that participates in cell growth by upregulating anabolic processes such as protein and lipid synthesis. Accordingly, emerging evidence suggests tha

APA, Harvard, Vancouver, ISO, and other styles

26

Diao, Mingxin, Yue Li, Zihui Gao, Chunji Wang, and Yaming Gu. "Comparison of prognosis after transurethral resection of bladder tumor between solitary and multiple bladder cancers." Medicine 103, no. 44 (2024): e40314. http://dx.doi.org/10.1097/md.0000000000040314.

Full text

Abstract:

This study investigates the difference in overall survival rates after transurethral resection of bladder tumor between solitary and multiple bladder cancers, aiming to provide guidance for clinical practitioners. A retrospective analysis was conducted on 133 patients with bladder cancer who underwent transurethral resection of bladder tumor from April 2017 to October 2023, of which 112 patients had complete clinical and follow-up data. Clinical and follow-up data were collected, and the overall survival rates after surgery were compared between solitary and multiple bladder cancers. In this s

APA, Harvard, Vancouver, ISO, and other styles

27

Shahriar, Mohammad Hasan, Mohammad Kamal, Tariqul Islam, Muhammad Rakibuz-Zaman, and Habibul Ahsan. "Tumor Burden in Bangladesh: A Pathology-Based Tumor Registry Overview." Journal of Global Oncology 3, no. 2_suppl (2017): 34s. http://dx.doi.org/10.1200/jgo.2017.009548.

Full text

Abstract:

Abstract 15 Background: Cancer is a public health concern in both developed and developing countries. Appropriate prevention and surveillance of cancer deserves urgent attention as incidence of the disease is expected to double in the next 20 to 25 years in most developing nations. Given the dearth of basic cancer-related data in Bangladesh and feasibility considerations, Bangabandhu Sheikh Mujib Medical University, in collaboration with University of Chicago, has continued a pathology-based tumor registry in Bangladesh for the last 4 years (from 2012 to present) at Bangabandhu Sheikh Mujib Me

APA, Harvard, Vancouver, ISO, and other styles

28

Gerke, Margo B., Caroline S. Jansen, and Mehmet A. Bilen. "Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications." Cancers 16, no. 12 (2024): 2280. http://dx.doi.org/10.3390/cancers16122280.

Full text

Abstract:

CtDNA is emerging as a non-invasive clinical detection method for several cancers, including genitourinary (GU) cancers such as prostate cancer, bladder cancer, and renal cell carcinoma (RCC). CtDNA assays have shown promise in early detection of GU cancers, providing prognostic information, assessing real-time treatment response, and detecting residual disease and relapse. The ease of obtaining a “liquid biopsy” from blood or urine in GU cancers enhances its potential to be used as a biomarker. Interrogating these “liquid biopsies” for ctDNA can then be used to detect common cancer mutations,

APA, Harvard, Vancouver, ISO, and other styles

29

Heit, John A., Tanya M. Petterson, Randolph S. Marks, Kent R. Bailey, and L. Joseph Melton. "The Risk of Venous Thromboembolism (VTE) among Cancer Patients by Tumor Site: A Population-Based Study." Blood 104, no. 11 (2004): 2596. http://dx.doi.org/10.1182/blood.v104.11.2596.2596.

Full text

Abstract:

Abstract Active cancer is an independent VTE risk factor (overall 6- to 9-fold increased risk) and accounts for almost 20% of all VTE in the community, but which cancer patients are at risk for VTE is largely unknown. Reportedly, VTE risk varies by tumor site, and cancer of the ovary, pancreas, colon, stomach, lung, prostate, and kidney convey particularly high VTE risk. Objective: To estimate VTE risk by tumor site. Methods: We enumerated observed cancers by tumor site for Olmsted County, MN active cancer patients with incident VTE over the seven-year period, 1991–1997 (n=152). We used 1991–1

APA, Harvard, Vancouver, ISO, and other styles

30

Akolkar, Dadasaheb, Darshana Patil, Raymond Page, et al. "Circulating ensembles of tumor-associated cells in gastrointestinal cancers." Journal of Clinical Oncology 38, no. 4_suppl (2020): 808. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.808.

Full text

Abstract:

808 Background: CEA and CA19-9 are non-specific markers for Gastrointestinal (GI) cancers. Molecular analysis of fecal blood is of limited utility in colorectal cancers. A non-invasive pan-GI-cancer blood-based test with high specificity and sensitivity is an unmet medical need. Considering that unprovoked thromboembolism is a significant risk in multiple cancers, we hypothesized that circulating thrombotic emboli in peripheral blood could comprise cancer cells and would serve as a reliable biomarker for detection of GI cancers. Methods: We obtained 15ml of blood from 7481 individuals, includi

APA, Harvard, Vancouver, ISO, and other styles

31

Kazbarienė, Birutė. "Tumor and immunity." Medicina 45, no. 2 (2009): 162. http://dx.doi.org/10.3390/medicina45020021.

Full text

Abstract:

System of organism defense is an important complex of interrelated cellular, molecular, genetic, and other components, which regulate homeostasis of host. Experimental and clinical data show that immune system functions are significant, but also a complicated question in cancer development. It is very important to investigate and understood how immune system coordinates the response to cancer cells. Our understanding about innate and adaptive immunity functions and interaction with transformed cells is constantly changing. Different responses of these system components can promote, reduce, or

APA, Harvard, Vancouver, ISO, and other styles

32

Gupta, Brinda, Sharon Wu, Sai-Hong Ignatius Ou, et al. "NRG1 fusions in solid tumors." Journal of Clinical Oncology 41, no. 16_suppl (2023): 3132. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3132.

Full text

Abstract:

3132 Background: NRG1 fusions are rare but actionable genomic drivers that occur across a growing number of tumor types. NRG1 has an EGF-like domain that serves as a ligand for ErbB (HER3) receptors, thereby inducing heterodimerization, usually with HER2, and subsequent activation of relevant downstream signaling pathways. Agents targeting the HER2/HER3 pathway have shown early clinical promise in NRG1 fusion-positive cancers: currently zenocutuzumab has FDA Fast Track Designation for tumors harboring NRG1-fusions. Here, we update the incidence and characterization of NRG1 fusions across tumor

APA, Harvard, Vancouver, ISO, and other styles

33

Liou, Geou-Yarh. "Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers." Journal of Immunology Research 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/7979637.

Full text

Abstract:

Inflammation is essential for many diseases including cancer. Activation and recruitment of immune cells during inflammation result in a cytokine- and chemokine-enriched cell environment, which affects cancer development. Since each type of cancer has its unique tumor environment, effects of cytokines from different sources such as tumor-infiltrating immune cells, stromal cells, endothelial cells, and cancer cells on cancer development can be quite complex. In this review, how immune cells contribute to tumorigenesis of pancreatic and prostate cancers through their secreted cytokines is discus

APA, Harvard, Vancouver, ISO, and other styles

34

Cohen, Ivan J., and Ronald Blasberg. "Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer." Breast Cancer: Basic and Clinical Research 11 (January 1, 2017): 117822341773156. http://dx.doi.org/10.1177/1178223417731565.

Full text

Abstract:

Immunotherapy is revolutionizing cancer care across disciplines. The original success of immune checkpoint blockade in melanoma has already been translated to Food and Drug Administration–approved therapies in a number of other cancers, and a large number of clinical trials are underway in many other disease types, including breast cancer. Here, we review the basic requirements for a successful antitumor immune response, with a focus on the metabolic and physical barriers encountered by lymphocytes entering breast tumors. We also review recent clinical trials of immunotherapy in breast cancer

APA, Harvard, Vancouver, ISO, and other styles

35

Mochimaru, Yuta, and Kiyotsugu Yoshida. "Functional Roles of DYRK2 as a Tumor Regulator." Current Issues in Molecular Biology 45, no. 10 (2023): 8539–51. http://dx.doi.org/10.3390/cimb45100538.

Full text

Abstract:

The dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) regulates the induction of apoptosis and DNA repair, metastasis inhibition, cell cycle G1/S transition, protein scaffold stability for E3 ligase complexes, and embryogenesis. Owing to these functions, DYRK2 is thought to regulate tumorigenesis, and its function in cancer has been investigated. Notably, DYRK2 has been reported to function as a tumor suppressor; however, it has also been reported to act as an oncogene in some cancers. This discrepancy makes it difficult to elucidate the conserved functions of DYRK2 in cance

APA, Harvard, Vancouver, ISO, and other styles

36

Chen, Chaoran, Yueming Ding, Huiyang Liu, Mengyao Sun, Honggang Wang, and Dongdong Wu. "Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers." International Journal of Molecular Sciences 23, no. 1 (2022): 519. http://dx.doi.org/10.3390/ijms23010519.

Full text

Abstract:

Flubendazole, belonging to benzimidazole, is a broad-spectrum insect repellent and has been repurposed as a promising anticancer drug. In recent years, many studies have shown that flubendazole plays an anti-tumor role in different types of cancers, including breast cancer, melanoma, prostate cancer, colorectal cancer, and lung cancer. Although the anti-tumor mechanism of flubendazole has been studied, it has not been fully understood. In this review, we summarized the recent studies regarding the anti-tumor effects of flubendazole in different types of cancers and analyzed the related mechani

APA, Harvard, Vancouver, ISO, and other styles

37

Gan, Xin, Yunqian Zeng, Jiaquan Huang, Xin Chen, Hao Kang, and Shuaiwen Huang. "Tumor-Derived Sarcopenia Factors Are Diverse in Different Tumor Types: A Pan-Cancer Analysis." Biomedicines 12, no. 2 (2024): 329. http://dx.doi.org/10.3390/biomedicines12020329.

Full text

Abstract:

Cancer-associated muscle wasting is a widespread syndrome in people with cancer and is characterized by weight loss and muscle atrophy, leading to increased morbidity and mortality. However, the tumor-derived factors that affect the development of muscle wasting and the mechanism by which they act remain unknown. To address this knowledge gap, we aimed to delineate differences in tumor molecular characteristics (especially secretion characteristics) between patients with and without sarcopenia across 10 tumor types from The Cancer Genome Atlas (TCGA). We integrated radiological characteristics

APA, Harvard, Vancouver, ISO, and other styles

38

Akshay, Sonaji Bhambre, Bhimrao Giri Ashok, Ashok Mundhe Swapnil, and Bharat Mahadik Arjun. "Precision and personalized medicine: new way for cancer management." GSC Biological and Pharmaceutical Sciences 18, no. 3 (2022): 046–53. https://doi.org/10.5281/zenodo.6392529.

Full text

Abstract:

Precision and personalized medicine (PPM) introduce to the tailoring of medical treatment to the individual characteristics of each patient. Cancer is one amongst the leading causes of death in India. Maximum chemotherapeutic agents are used for cancer patients, but lack of long-time effectiveness and severe side effects from these agents, to improve therapeutic outcome to developed new tool called PPM as follow. Better understanding of pharmacogenomics has been help to developed and the potential for customizing health care for cancers patients. Recently, PPM has mainly involved the systemati

APA, Harvard, Vancouver, ISO, and other styles

39

Han, Yi-chun, David Hsieh, and Shian-Jiun (SJ) Shih. "Abstract 4003: Improved drug screening and resistance monitoring using cancer organoids derived from dissociated tumor cells and circulating tumor cells." Cancer Research 85, no. 8_Supplement_1 (2025): 4003. https://doi.org/10.1158/1538-7445.am2025-4003.

Full text

Abstract:

Abstract Cancer is a complicated disease, and despite recent breakthroughs in cancer treatment, cancer remains the second leading cause of death globally, with metastatic cancers responsible for the large majority. To develop effective cancer drugs, we need reliable in vitro models that represent cancers accurately, particularly for metastatic cancers. However, current experimental models of human cancers in vitro face several limitations. Well-established cell lines typically emerged from long-term exposure to simple tissue culture conditions, while genomic and epigenetic instability contribu

APA, Harvard, Vancouver, ISO, and other styles

40

Weidemann, Sören, Natalia Gorbokon, Maximilian Lennartz, et al. "Abstract 3303: High homogeneity of mesothelin expressionin primary and metastatic ovarian cancer." Cancer Research 83, no. 7_Supplement (2023): 3303. http://dx.doi.org/10.1158/1538-7445.am2023-3303.

Full text

Abstract:

Abstract Background: Mesothelin is a glycosylphosphatidylinositol-anchored cell surface protein of widely unknown function that may play a role in tumor growth control. Because mesothelin is overexpressed in a variety of human cancer types including ovarian cancers, it represents an attractive target for novel therapies employing adaptive T-cell transfer in these tumors. However, tumor heterogeneity is a challenge for targeted therapies. Methods: To study the extent of heterogeneity of mesothelin overexpression in primary ovarian cancers and their peritoneal and lymph node metastases, a tissue

APA, Harvard, Vancouver, ISO, and other styles

41

Sun, Hao, Ying Zheng, Ryan Strauch, Yi Zhang, Minqi Huang, and Luke Tsai. "Abstract 1361: Severe hyperglycemia and hyperlipidemia alters tumor growth and immune profiles in syngeneic tumor models." Cancer Research 85, no. 8_Supplement_1 (2025): 1361. https://doi.org/10.1158/1538-7445.am2025-1361.

Full text

Abstract:

Background and Objective: The global prevalence of obesity is increasing rapidly, causing the rise of obesity-associated diseases, such as diabetes and cancers. It has been established that obesity increases the risks for various types of cancers. Over the past decades, studies have proposed that obesity promotes cancer progression through mechanisms like chronic low-grade inflammation, which alters immune responses and the tumor microenvironment, ultimately affecting tumor response to therapies. Previous studies in diet induced obese models showed T cells in the colorectal cancer are reduced

APA, Harvard, Vancouver, ISO, and other styles

42

Srinivasan, Ajay, Dadasaheb B. Akolkar, Pradip Fulmali, et al. "Circulating ensembles of tumor-associated cells in genitourinary cancers." Journal of Clinical Oncology 38, no. 6_suppl (2020): 718. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.718.

Full text

Abstract:

718 Background: Detection of genitourinary cancers is based on histopathological analysis of tumor tissue obtained by invasive biopsies following manifestation of clinical or radiological symptoms. There is presently no non-invasive blood-based test with high specificity and sensitivity for detection of genitourinary cancers. Considering that unprovoked thromboembolism is a significant risk in multiple cancers, we hypothesized that tumor derived circulating emboli in peripheral blood could comprise cancer cells and would serve as a reliable biomarker for detection of genitourinary cancers. The

APA, Harvard, Vancouver, ISO, and other styles

43

N, Chaitra, Sundar RNS, Kumar HKS, Nataraju G, and Esaivani KB. "Tumor budding in colorectal adenocarcinoma using cytokeratin 20 immunostaining." Journal of Medical and Scientific Research 11, no. 4 (2023): 285–89. http://dx.doi.org/10.17727/jmsr.2023/11-53.

Full text

Abstract:

Introduction: Colorectal cancer is the third most common cancer worldwide and second most common fatal cancer. Tumor budding is an emerging prognostic indicator in cancers. Though tumor budding can be assessed using Hematoxylin and Eosin stain, sometimes peritumoral inflammation and reactive stromal fibrosis obscures the tumor buds. The present study aimed to assess tumor budding using cytokeratin 20 immunohistochemistry in colorectal cancers. Methods: This is a cross sectional study which included 30 cases of colorectal carcinomas. cytokeratin 20 stained slides of colorectal carcinoma were as

APA, Harvard, Vancouver, ISO, and other styles

44

Gajim, Sabina, and Ion Mereuță. "CANCER AND MAJOR METABOLIC RISKS." Deutsche internationale Zeitschrift für zeitgenössische Wissenschaft 100 (March 20, 2025): 22–24. https://doi.org/10.5281/zenodo.15061509.

Full text

Abstract:

Cancer and metabolic syndrome (MetS) are major public health concerns, both with increasing prevalence. This study investigates the relationship between major metabolic risks (hypertension - HTN, diabetes mellitus -DM, obesity) and cancer incidence in a sample of 120 patients diagnosed with six common cancer types in the Republic of Moldova (breast, lung, gastric, colon, renal, skin cancer). A retrospective analysis revealed a significant association between metabolic syndrome and the studied cancers, with a higher prevalence of metabolic comorbidities in gastric cancer (85%) and colon cancer

APA, Harvard, Vancouver, ISO, and other styles

45

Hampel, Heather. "Abstract IA004: Universal tumor screening for Lynch syndrome versus germline multi-gene panel testing for all endometrial cancer patients." Clinical Cancer Research 30, no. 5_Supplement (2024): IA004. http://dx.doi.org/10.1158/1557-3265.endo24-ia004.

Full text

Abstract:

Abstract Introduction: Implementation of universal tumor screening for Lynch syndrome has been adopted more slowly for endometrial cancer patients than colorectal cancer patients yet the data is very similar. Recent guidelines have suggested doing both universal tumor screening and considering multi-gene panel testing for all colorectal cancer patients and so the data in endometrial cancer patients was reviewed to determine if the same recommendation could be made for endometrial cancer. Methods: Review of the literature found 4 large studies of universal tumor screening for Lynch syndrome amo

APA, Harvard, Vancouver, ISO, and other styles

46

Nadhan, Revathy, Srishti Kashyap, Ji Hee Ha, et al. "Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies." Metabolites 13, no. 5 (2023): 618. http://dx.doi.org/10.3390/metabo13050618.

Full text

Abstract:

Peritoneal cancers present significant clinical challenges with poor prognosis. Understanding the role of cancer cell metabolism and cancer-promoting metabolites in peritoneal cancers can provide new insights into the mechanisms that drive tumor progression and can identify novel therapeutic targets and biomarkers for early detection, prognosis, and treatment response. Cancer cells dynamically reprogram their metabolism to facilitate tumor growth and overcome metabolic stress, with cancer-promoting metabolites such as kynurenines, lactate, and sphingosine-1-phosphate promoting cell proliferati

APA, Harvard, Vancouver, ISO, and other styles

47

Looi, Chin-King, Ling-Wei Hii, Siew Ching Ngai, Chee-Onn Leong, and Chun-Wai Mai. "The Role of Ras-Associated Protein 1 (Rap1) in Cancer: Bad Actor or Good Player?" Biomedicines 8, no. 9 (2020): 334. http://dx.doi.org/10.3390/biomedicines8090334.

Full text

Abstract:

Metastasis is known as the most life-threatening event in cancer patients. In principle, the immune system can prevent tumor development. However, dysfunctional T cells may fail to eliminate the tumor cells effectively and provide additional survival advantages for tumor proliferation and metastasis. Constitutive activation of Ras-associated protein1 (Rap1) has not only led to T cell anergy, but also inhibited autophagy and supported cancer progression through various oncogenic events. Inhibition of Rap1 activity with its negative regulator, Rap1GAP, impairs tumor progression. However, active

APA, Harvard, Vancouver, ISO, and other styles

48

Jiramonai, Luksika, Xing-Jie Liang, and Mengliang Zhu. "Extracellular Vesicle-Based Strategies for Tumor Immunotherapy." Pharmaceutics 17, no. 2 (2025): 257. https://doi.org/10.3390/pharmaceutics17020257.

Full text

Abstract:

Immunotherapy is one of the most promising approaches for cancer management, as it utilizes the intrinsic immune response to target cancer cells. Normally, the human body uses its immune system as a defense mechanism to detect and eliminate foreign objects, including cancer cells. However, cancers develop a ‘switch off’ mechanism, known as immune checkpoint proteins, to evade immune surveillance and suppress immune activation. Therefore, significant efforts have been made to develop the strategies for stimulating immune responses against cancers. Among these, the use of extracellular vesicles

APA, Harvard, Vancouver, ISO, and other styles

49

Dillen, Ana, Indy Bui, Megan Jung, Stephanie Agioti, Apostolos Zaravinos, and Benjamin Bonavida. "Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1." Cancers 16, no. 6 (2024): 1237. http://dx.doi.org/10.3390/cancers16061237.

Full text

Abstract:

During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host’s immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to

APA, Harvard, Vancouver, ISO, and other styles

50

SHAHLA, YAZDANI, BOUZARI ZINATOSSADAT, JAMALI SAHAR, VAKILI MOHSEN, and AKRAM SADAT. "EARLY SYMPTOMS OF OVARIAN CANCER." Journal of Medicine and Health Research 2, no. 2 (2017): 59–64. https://doi.org/10.5281/zenodo.1413003.

Full text

Abstract:

<strong>Background:</strong> Ovarian cancer is the sixth most prevalent cancer among women and the most common cause of death in the gynecological cancers. Due to their histological structure, ovarian tumors are variable and they have wide nonspecific primary clinical symptoms. The aim of this study was to determine the early symptoms of ovarian cancer in Shahid Rajaee and Rouhani hospitals of Babol. <strong>Materials and Methods:</strong> This retrospective study was performed on 71 patients with ovarian cancer who were referred to Shahid Rajaee and Rouhani hospitals of Babol. Information rec

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!